Phrenno-F.6 (Olanzapine & Fluoxetine) Capsules: Advanced Combination Care for Bipolar Depression
Managing the severe depressive phases of manic depression demands a multi-targeted clinical approach. Phrenno-F.6 capsules offer a powerful, dual-mechanism therapeutic option designed specifically for the treatment of depression caused by Bipolar disorder. By bringing together two distinct classes of psychiatric medication into a single capsule, Phrenno-F.6 works to safely rebalance erratic brain chemistry, offering renewed hope and mood stability for patients navigating complex emotional lows.
-
Synergistic Dual-Action Formula: Phrenno-F.6 utilizes the combined strength of Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and Olanzapine, a proven antipsychotic drug. Together, they target multiple neural pathways simultaneously to provide more comprehensive relief than standard single-drug therapies.
-
Targeted Bipolar Depression Relief: This specific formulation is highly indicated for managing the deep, debilitating depressive episodes associated with Bipolar disorder (commonly referred to as Manic Depression).
-
Effective Strategy for Treatment Resistance: Finding the right psychiatric treatment can be a long journey. The Fluoxetine and Olanzapine combination found in Phrenno-F.6 is widely recognized as an essential intervention that is sometimes given after other standard medications have failed to work.
-
Precise Strength Configuration: The F.6 variant offers the mid-dose configuration of the Phrenno line, allowing healthcare providers to step up the Olanzapine component to 6mg alongside a steady 25mg baseline of Fluoxetine to best suit the patient’s evolving clinical needs.







Reviews
There are no reviews yet.